Жанры
Авторы
Контакты
О сайте
Книжные новинки
Популярные книги
Найти
Главная
Авторы
Группа авторов
Drug Transporters
Читать книгу Drug Transporters - Группа авторов - Страница 1
Оглавление
Предыдущая
Следующая
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
...
139
Оглавление
Купить и скачать книгу
Вернуться на страницу книги Drug Transporters
Оглавление
Страница 1
Table of Contents
List of Tables
List of Illustrations
Guide
Pages
Страница 7
DRUG TRANSPORTERS Molecular Characterization and Role in Drug Disposition
Страница 9
Страница 10
LIST OF CONTRIBUTORS
PREFACE
1 OVERVIEW OF DRUG TRANSPORTER FAMILIES
1.1 INTRODUCTION
1.2 WHAT ARE DRUG TRANSPORTERS?
1.3 STRUCTURE AND MODEL OF DRUG TRANSPORTERS
1.4 TRANSPORT MECHANISMS
1.5 POLARIZED EXPRESSION OF DRUG TRANSPORTERS IN BARRIER EPITHELIUM
1.6 CLASSIFICATIONS OF DRUG TRANSPORTERS
1.6.1 Definition of Efflux and Influx Transporters
1.6.2 Definition of Absorptive and Secretory Transporters
1.6.3 Relationship Between Influx/Efflux and Absorptive/Secretory Transporters
1.6.4 ABC Transporters and SLC Transporters
1.7 NOMENCLATURE OF DRUG TRANSPORTERS
1.8 REGULATION OF DRUG TRANSPORTERS
1.9 CONCLUSION
REFERENCES
2 ORGANIC CATION AND ZWITTERION TRANSPORTERS
2.1 OVERALL INTRODUCTORY SECTION
CATION TRANSPORTERS: OCT1, OCT2, OCT3 (OTHER SECTION: SLC19A2, SLC19A3, PMAT) 2.2 INTRODUCTION TO THE OCT FAMILY
2.2.1 Tissue Distribution
2.2.2 Structure–Function Relationships
2.2.3 Transport Mechanism
2.3 OCT1 2.3.1 Substrate and Inhibitor Selectivity
2.3.2 Regulation
2.3.3 Animal Models
2.3.4 Human Genetic Studies
2.3.5 Biomarkers and FDA Guidances for Transporter‐Mediated DDIs
2.4 OCT2 2.4.1 Substrate and Inhibitor Selectivity
2.4.2 Regulation
2.4.3 Animal Models
2.4.4 Human Genetic Studies
2.5 OCT3 2.5.1 Substrate and Inhibitor Selectivity
2.5.2 Regulation
2.5.3 Animal Models
2.5.4 Human Genetic Studies
2.6 OTHER IMPORTANT CATION TRANSPORTERS: SLC19A2, SLC19A3 (THIAMINE TRANSPORTERS), SLC29A4 (MONOAMINE TRANSPORTER) 2.6.1 Introduction
2.6.2 Tissue Distribution in Human
2.6.3 Substrate and Inhibitor Selectivity
2.6.4 Animal Models
2.6.5 Human Genetic Studies
ZWITTERION TRANSPORTERS: OCTN1, OCTN2, SLC22A15 AND SLC22A16 (OTHER SECTION: OCTN3) 2.7 INTRODUCTION TO THE ZWITTERION TRANSPORTERS
2.7.1 General Tissue Distribution
2.7.2 General Structure Function
2.7.3 Transport Mechanism
2.8 OCTN1 2.8.1 Substrate and Inhibitor Selectivity
2.8.2 Regulation
2.8.3 Animal Models
2.8.4 Human Genetic Studies
2.9 OCTN2 2.9.1 Substrate and Inhibitor Selectivity
2.9.2 Regulation
2.9.3 Animal Models
2.9.4 Human Genetic Studies
2.10 SLC22A15 2.10.1 Introduction
2.10.2 Substrate and Inhibitor Selectivity
2.10.3 Human Genetic Studies
2.11 SLC22A16 (FLIPT2, CT2, OCT6) 2.11.1 Introduction
2.11.2 Substrate and Inhibitor Selectivity
2.11.3 Regulation
2.11.4 Human Genetic Studies
2.12 OCTN3 2.12.1 Introduction
2.12.2 Substrate and Inhibitor Selectivity
2.12.3 Regulation
2.13 CONCLUSION
REFERENCES
3 MULTIDRUG AND TOXIN EXTRUSION PROTEINS
3.1 INTRODUCTION
3.2 TISSUE AND SUBCELLULAR DISTRIBUTION 3.2.1 Tissue Distribution
3.2.2 Subcellular Localization
3.3 TRANSPORT ACTIVITY
3.3.1 Energetics of Transport
3.3.2 Substrates
3.3.2.1 Metformin
3.3.2.2 Platinum Drugs
3.3.2.3 Cardiovascular Drugs
3.3.2.4 Alkaloids
3.3.2.5 Paraquat
3.3.2.6 Endogenous Molecules
3.3.3 Inhibitors
3.4 STRUCTURE 3.4.1 Modeling of Ligand Interactions
3.4.2 Secondary Structure
3.4.3 Structural Features
3.5 EXPRESSION AND REGULATION 3.5.1 Transcriptional Regulation
3.5.2 Short‐Term Regulation
3.5.3 Sex and Age
3.5.4 Pregnancy
3.5.5 Disease Models
3.5.5.1 Kidney Disease and Injury
3.5.5.2 Liver Disease and Injury
3.6 DRUG EFFICACY AND TOXICITY 3.6.1 Clinical Substrates, Probes, and Inhibitors
3.6.2 Pharmacokinetic Drug Interactions
3.6.2.1 Metformin
3.6.2.2 Physiologically Based Pharmacokinetic Methods to Assess Interactions
3.6.2.3 Serum Creatinine and Kidney Function
3.6.2.4 Other Endogenous Probe SubstratesNMN has
3.7 PHARMACOGENETICS
3.7.1 Metformin Pharmacokinetics
3.7.2 Metformin Efficacy
3.7.2.1 Diabetes
3.7.2.2 Nondiabetes Indications
3.7.3 Cisplatin Toxicity
3.7.4 Flutamide Liver Injury
3.8 CONCLUSIONS
ACKNOWLEDGMENT
REFERENCES
4 ORGANIC ANION TRANSPORTERS (OATs)
4.1 OAT FAMILY 4.1.1 Introduction
4.1.2 Discovery
4.1.3 Nomenclature
4.2 MOLECULAR CHARACTERIZATION 4.2.1 Genomics
4.2.2 Protein Structure
4.2.3 Mechanism of Substrate Translocation
4.3 EXPRESSION AND REGULATION OF OATS 4.3.1 Tissue Distribution
4.3.2 Ontogeny
4.3.3 Transcriptional Regulation
4.3.4 Post‐translational Regulation
4.4 OAT SUBSTRATES AND DRUG–DRUG (DRUG–METABOLITE) INTERACTION 4.4.1 Substrates
4.4.2 Substrate Specificity
4.4.3 Inhibitors
4.4.4 Natural Products and Herbal Medicines
4.4.5 Drug–Drug Interactions and Drug–Metabolite Interactions
4.5 SYSTEMS BIOLOGY OF OATS 4.5.1 Physiological Role
4.5.2 Metabolic Pathways Regulated by OATs
4.5.3 Chronic Kidney Disease and Uremic Toxins
4.5.4 Pathophysiology
4.5.5 Clinical Pharmacology
4.5.6 Remote Sensing and Signaling Theory
4.6 CONCLUSIONS
ACKNOWLEDGMENTS
REFERENCES
{buyButton}
Подняться наверх
